Lazard Upgrades XenoPort (XNPT) to Buy
More News related to XNPT
- Glaxo (GSK) and XenoPort's (XNPT) NDA for Solzira(TM) Withdrawn
- Morning Movers 11/10: AIG (AIG) Up On Restrtucted Bailout, Circuit City (CC) Sinks On Bankruptcy
- GSK and XenoPort Announce Plans to Withdraw and Resubmit New Drug Application Requesting Approval of Solzira(TM) for Restless Legs Syndrome
- XenoPort to Present at Upcoming Conferences
- XenoPort Reports Third Quarter Financial Results
More News related to Upgrades
- Sandler O'Neill Upgrades Wintrust Financial (WTFC) to Hold
- Gabelli & Co. Upgrades Barnes Group (B) to Buy
- Matrix Upgrades/Downgrades for December 1, 2008
- Wall Street Access Upgrades Cummins (CMI) to Buy
- RBC Capital Upgrades Hospitality Properties Trust (HPT) to Outperform
Lazard Capital upgrades XenoPort (Nasdaq: XNPT) from Hold to Buy.
XenoPort, Inc., a biopharmaceutical company, focuses on developing internally-discovered product candidates that utilize the body's natural nutrient transporter mechanisms.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
